Insider Transactions Reported by 14 Insiders of Atea Pharmaceuticals, Inc.

Symbol
AVIR on Nasdaq
Location
Boston, MA

There are no Buy or Sell transactions made by insiders since 14 Feb 2025

Atea Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Jean-Pierre Sommadossi President, CEO, and Chairman, Director $22,198,343 31 Jan 2026
Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal and Secretary $3,269,692 31 Jan 2026
Franklin Berger Director $1,526,418 20 Jun 2025
John Vavricka Chief Commercial Officer $671,526 31 Jan 2026
Janet MJ Hammond Chief Development Officer $575,724 31 Jan 2026
Maria Arantxa Horga Chief Medical Officer $437,239 31 Jan 2026
Bruno Lucidi Director $419,989 20 Jun 2025
Bruce Polsky Director $385,928 20 Jun 2025
Wayne Foster EVP, Chief Accounting Officer $363,245 31 Jan 2026
Polly A. Murphy Director $360,186 20 Jun 2025
Barbara Gayle Duncan Director $279,489 20 Jun 2025
Jerome M. Adams Director $279,489 20 Jun 2025
ARTHUR S. KIRSCH Director $139,873 20 Feb 2025
Howard Berman Director 20 Jun 2025

Recent Insider Transactions by Companies or Individuals for Atea Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.